HighWire Wilson and colleagues, in an open study of patients with chronic rhinosinusitis, showed a benefit of adding montelukast.The investigators would like to recruit perennially allergic subjects and place them on fluticasone for 2 weeks. Please enable it to take advantage of the complete set of features! Unable to load your collection due to an error The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.The change from baseline for each subsequent day of treatment was then calculated for each subject. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. 2008 Aug;30(8):1492-504. doi: 10.1016/j.clinthera.2008.07.018.Clin Ther. Secondary end points, including percentage of predicted forced expiratory volume in 1 second value, days with beta-receptor agonist use, and quality … Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma Ann Allergy Asthma Immunol . The purpose of this study was to compare the addition of MON to patients receiving FSC on asthma control while experiencing asth …
Limited information exists comparing fluticasone propionate/salmeterol combination (FSC) versus montelukast (MON) in patients with coexistent asthma and allergic rhinitis. Clipboard, Search History, and several other advanced features are temporarily unavailable. HighWire We report the median and full range of these average changes for each group.A negative value indicates an improvement in symptoms.Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). We report the median and full range of these average changes for each group.A negative value indicates an improvement in symptoms.Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. 2005 Aug;116(2):493-5. doi: 10.1542/peds.2005-1231.Pediatrics.
Unable to load your delegates due to an error 2002 Feb;88(2):227-35. doi: 10.1016/S1081-1206(10)62001-7. eCollection 2015 May.Hossny E, Rosario N, Lee BW, Singh M, El-Ghoneimy D, Soh JY, Le Souef P.World Allergy Organ J. 2016 Aug 12;9:26. doi: 10.1186/s40413-016-0117-0. Clinicians frequently prescribe an oral H1 antihistamine for allergic rhinitis patients with residual symptoms after taking an intranasal steroid. 2015 Sep 14;1(1):00022-2015. doi: 10.1183/23120541.00022-2015. 2020 Aug 11;6(3):00359-2019. doi: 10.1183/23120541.00359-2019. 2019 Jun;6(3):594-602. doi: 10.1007/s40615-018-00558-5. Name must be less than 100 characters The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.The change from baseline for each subsequent day of treatment was then calculated for each subject. We report the median and full range of these average changes for each group.A negative value indicates an improvement in symptoms.